Surfactant replacement therapy for neonatal respiratory distress syndrome

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Surfactant treatment of RDS improves oxygcnation and ventilation whether given immediately after birth or after the onset of the disease. There is also a decrease in associated morbidity (air leak), and improved survival with no significant short term side effects. Information about long term follow-up is limited, but encouraging. The future should bring better surfactants (recombinant DNA human surfactant) and optimization of timing, multiplicity and size of dose, and technique of ventilation. This will allow for the survival of most of the premature infants beyond 25 weeks gestation with minimal morbidity. Surfactant treatment of RDS will go down as a true landmark in the history of neonatology.

Original languageEnglish (US)
Pages (from-to)743-749
Number of pages7
JournalThe Indian Journal of Pediatrics
Volume57
Issue number6
DOIs
StatePublished - Nov 1 1990
Externally publishedYes

Fingerprint

Newborn Respiratory Distress Syndrome
Surface-Active Agents
Ventilation
Neonatology
Morbidity
Survival
Recombinant DNA
Therapeutics
Premature Infants
History
Air
Parturition
Pregnancy

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Surfactant replacement therapy for neonatal respiratory distress syndrome. / Dhanireddy, Ramasubbareddy.

In: The Indian Journal of Pediatrics, Vol. 57, No. 6, 01.11.1990, p. 743-749.

Research output: Contribution to journalArticle

@article{c6161614952847528f35f94d2b818eac,
title = "Surfactant replacement therapy for neonatal respiratory distress syndrome",
abstract = "Surfactant treatment of RDS improves oxygcnation and ventilation whether given immediately after birth or after the onset of the disease. There is also a decrease in associated morbidity (air leak), and improved survival with no significant short term side effects. Information about long term follow-up is limited, but encouraging. The future should bring better surfactants (recombinant DNA human surfactant) and optimization of timing, multiplicity and size of dose, and technique of ventilation. This will allow for the survival of most of the premature infants beyond 25 weeks gestation with minimal morbidity. Surfactant treatment of RDS will go down as a true landmark in the history of neonatology.",
author = "Ramasubbareddy Dhanireddy",
year = "1990",
month = "11",
day = "1",
doi = "10.1007/BF02722267",
language = "English (US)",
volume = "57",
pages = "743--749",
journal = "Indian Journal of Pediatrics",
issn = "0019-5456",
publisher = "Springer India",
number = "6",

}

TY - JOUR

T1 - Surfactant replacement therapy for neonatal respiratory distress syndrome

AU - Dhanireddy, Ramasubbareddy

PY - 1990/11/1

Y1 - 1990/11/1

N2 - Surfactant treatment of RDS improves oxygcnation and ventilation whether given immediately after birth or after the onset of the disease. There is also a decrease in associated morbidity (air leak), and improved survival with no significant short term side effects. Information about long term follow-up is limited, but encouraging. The future should bring better surfactants (recombinant DNA human surfactant) and optimization of timing, multiplicity and size of dose, and technique of ventilation. This will allow for the survival of most of the premature infants beyond 25 weeks gestation with minimal morbidity. Surfactant treatment of RDS will go down as a true landmark in the history of neonatology.

AB - Surfactant treatment of RDS improves oxygcnation and ventilation whether given immediately after birth or after the onset of the disease. There is also a decrease in associated morbidity (air leak), and improved survival with no significant short term side effects. Information about long term follow-up is limited, but encouraging. The future should bring better surfactants (recombinant DNA human surfactant) and optimization of timing, multiplicity and size of dose, and technique of ventilation. This will allow for the survival of most of the premature infants beyond 25 weeks gestation with minimal morbidity. Surfactant treatment of RDS will go down as a true landmark in the history of neonatology.

UR - http://www.scopus.com/inward/record.url?scp=0025517995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025517995&partnerID=8YFLogxK

U2 - 10.1007/BF02722267

DO - 10.1007/BF02722267

M3 - Article

VL - 57

SP - 743

EP - 749

JO - Indian Journal of Pediatrics

JF - Indian Journal of Pediatrics

SN - 0019-5456

IS - 6

ER -